SSRIs and suicidality: effects of SSRIs on rating-scale-assessed suicidality in adults with depression


Rina Dutta and Patrick McLaughlin summarise a new study looking at the effects of SSRIs (Selective Serotonin Reuptake Inhibitors) on rating-scale-assessed suicidality in adults with depression.

This study published in the British Journal of Psychiatry supports the conclusion that SSRIs remain a safe and effective treatment in depression for those aged 18 and over.

[read the full story...]

Depression in later life: who benefits most from antidepressants plus exercise?


Linda Gask explores an RCT of physical exercise for depression in later life, which considers the best way to customise the intervention for primary care.

[read the full story...]

Adding antidepressants to antipsychotics in schizophrenia: do they work, for what, and are they safe?


Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and schizophrenia-like psychosis.

[read the full story...]

Antidepressants: benefits and harms in children and adults


Samei Huda discusses the findings of a recent review into suicidality and aggression during antidepressant treatment. The systematic review and meta-analyses were based on clinical study reports and included some important adverse effects of antidepressants in children and young people.

[read the full story...]

Pharmacotherapy for anxiety and comorbid alcohol use disorders


Natasha Clarke summarises a recent Cochrane review of pharmacotherapy for anxiety and comorbid alcohol use disorders, which found only very low quality evidence about the effectiveness of medication (buspirone, paroxetine, sertraline) for treating patients with both conditions.

[read the full story...]

CBT is more cost-effective than SSRI alone as treatment for panic disorder


In addition to its impact on quality of life, panic disorder can have a number of costly consequences such as lost productivity – particularly if also associated with agoraphobia. Cost-effectiveness is therefore an important consideration in choosing the optimal treatment for panic disorder, which might improve value via the cost side of the equation. A recent [read the full story…]